Nassar M, Gill AS, Marte E. Investigating the impact of intestinal glucagon-like peptide-1 on hypoglycemia in type 1 diabetes. World J Diabetes 2025; 16(3): 99142 [DOI: 10.4239/wjd.v16.i3.99142]
Corresponding Author of This Article
Mahmoud Nassar, MD, PhD, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Mar 15, 2025; 16(3): 99142 Published online Mar 15, 2025. doi: 10.4239/wjd.v16.i3.99142
Investigating the impact of intestinal glucagon-like peptide-1 on hypoglycemia in type 1 diabetes
Mahmoud Nassar, Angad Singh Gill, Erlin Marte
Mahmoud Nassar, Angad Singh Gill, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY 14221, United States
Mahmoud Nassar, Angad Singh Gill, Department of Research, American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE), Lewes, DE 19958, United States
Erlin Marte, Department of Endocrine, WNY VA Hospital, Buffalo, NY 14215, United States
Author contributions: Nassar M, Gill AS and Marte E contributed equally to the conceptualization, methodology, investigation, writing (original draft preparation and review & editing), and final approval of the manuscript; Each author has agreed to the published version of the manuscript.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this paper.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mahmoud Nassar, MD, PhD, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Received: July 14, 2024 Revised: November 30, 2024 Accepted: January 2, 2025 Published online: March 15, 2025 Processing time: 190 Days and 14.3 Hours
Abstract
Recent advances in understanding type 1 diabetes (T1D) highlight the complexity of managing hypoglycemia, a frequent and perilous complication of diabetes therapy. This letter delves into a novel study by Jin et al, which elucidates the role of intestinal glucagon-like peptide-1 (GLP-1) in the counterregulatory response to hypoglycemia in T1D models. The study employed immunofluorescence, Western blotting, and enzyme-linked immunosorbent assay to track changes in GLP-1 and its receptor expression in diabetic mice subjected to recurrent hypoglycemic episodes. Findings indicate a significant increase in intestinal GLP-1 and GLP-1 receptor expression, correlating with diminished adrenal and glucagon responses, crucial for glucose stabilization during hypoglycemic events. This letter aims to explore the implications of these findings for future therapeutic strategies and the broader understanding of T1D management.
Core Tip: This study unveils a novel role of intestinal glucagon-like peptide-1 (GLP-1) in type 1 diabetes (T1D) hypoglycemia management. It reveals that increased GLP-1 and GLP-1 receptor expression in the intestine correlates with reduced adrenal and glucagon responses, which are crucial for glucose stabilization during hypoglycemic episodes. These findings suggest a significant modulation of hormonal counter-regulation pathways by intestinal GLP-1, pointing towards new therapeutic approaches that could better manage hypoglycemia in T1D without compromising natural counterregulatory mechanisms.
